New York Life Investment Management’s Inhibrx, Inc. Common Stock INBX Stock Holding History

New York Life Investment Management’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-40,976	Closed	-$1.43M	–	1383
2024 Q1	$1.43M	Buy	+40,976	New	+$1.49M	0.01%	605
2023 Q1	–	Sell	-25,458	Closed	-$627K	–	1472
2022 Q4	$627K	Buy	25,458 +2,869	+13%	+$84.3K	0.01%	742
2022 Q3	$405K	Buy	22,589 +1,658	+8%	+$29.9K	﹤0.01%	936
2022 Q2	$238K	Buy	+20,931	New	+$308K	﹤0.01%	1208

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

New York Life Investment Management's INBX Position: Q2 2024 in Review

New York Life Investment Management sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 40,976 shares — an estimated $1.43M sold.

New York Life Investment Management first reported a position in INBX in Q2 2022 and held it in 4 quarters. The position peaked at $1.43M in Q1 2024. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

New York Life Investment Management reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
New York Life Investment Management sold 40,976 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $1.43M.
New York Life Investment Management first reported a position in Inhibrx, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
New York Life Investment Management's Inhibrx, Inc. Common Stock position peaked at $1.43M in Q1 2024.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.